ATAI
demonstrated safety level and plasma concentrations of in line with previous trials potential therapeutic plasma levels no serious adverse events reported asymptomatic prolongation phase study trial design results summary | ATAI
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
23 of 34
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
October 2023
demonstrated safety level and plasma concentrations of in line with previous trials phase study trial design results summary | ATAI
Related slides by other companies
Hepion Pharmaceuticals
Results
October 2022
phase studies completed safe and well tolerated key findings | Hepion Pharmaceuticals
BrainStorm Cell Therapeutics
Investor Presentation
October 2022
phase trial study design designed to exclude slow | BrainStorm Cell Therapeutics
Compass Therapeutics
Investor Presentation
May 2023
phase study design compass | Compass Therapeutics
Checkmate Pharmaceuticals
IPO
August 2020
phase study design | Checkmate Pharmaceuticals
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io